IDYA - Latest News
IDEAYA Biosciences, Inc. (IDYA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $3.26B. Beta to the broader market is -0.09.
The article list below shows the most recent IDYA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IDYA Headlines
IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock
defenseworld.net - Oct 11, 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction that occurr
IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened
defenseworld.net - Sep 30, 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s stock price traded up 4.
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
prnewswire.com - Sep 28, 2026
SOUTH SAN FRANCISCO, Calif. , Sept.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com - Sep 25, 2026
SOUTH SAN FRANCISCO, Calif. , Sept.
Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA
defenseworld.net - Sep 18, 2026
Squarepoint Ops LLC reduced its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 74.
How News Affects IDYA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IDYA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IDYA news questions
- What is the latest IDYA news headline?
- The most recent IDYA headline (Oct 11, 2026) is "IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IDYA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IDYA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IDYA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.